TY - JOUR
T1 - Cyclic Melanotropins. 9.17-D-Phenylalanine Analogues of the Active-Site Sequence
AU - Cody, Wayne L.
AU - Mahoney, Mark
AU - Knittel, James J.
AU - Hruby, Victor J.
AU - Castrucci, Ana Maria de L.
AU - Hadley, Mac E.
PY - 1985
Y1 - 1985
N2 - The cyclic melanotropin Ac-Ser1-Tyr2-Ser3-Cys4-Glu6-His6-Phe7-Arg8-Trp9-Cys10-Lys11-Pro12-Val13-NH2is a highly potent agonist as determined in several melanocyte bioassays. In linear melanotropins, a D-Phe7substitution leads to increased potency and often prolonged biological activity. In order to determine if this substitution would have the same effect in cyclic melanotropins, we have prepared a series of these analogues. The D-Phe7-substituted cyclic melanotropins Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_10-NH2 and Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_n-NH2were both more potent than their cyclic L-Phe7-containing counterparts in either the frog or lizard skin bioassay by more than a factor of 10. Neither peptide, however, exhibited prolongation of biological activity in either assay. Substitution of D-Phe7into the cyclic 4–12 and 4~13 sequences led to a slight or no increase in potency in both assays relative to the L-Phe7counterparts, but the activity of the melanotropins was ultraprolonged in each assay. Ac- [Cys4,D-Phe7,Cys10]-α-MSH4_12-NH2was about equipotent to Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_13-NH2, again demonstrating as with certain linear and cyclic L-Phe7-containing melanotropins, that the C-terminal amino acid valine is not required for biological activity or for superpotency. Similar to the linear D-Phe7analogues that possessed ultraprolonged melanotropic activity, the 4–12 and 4–13 cyclic D-Phe7analogues also displayed the phenomenon of superagonism, which is a time-dependent increase in efficacy over that produced by an equipotent concentration of the native hormone. Cyclization of certain linear melanotropins resulted in analogues with increased resistance to biological degradation by serum enzymes or purified proteolytic enzymes. Further, incorporation of a D-Phe7into in the cyclic analogues led to melanotropins that were totally resistant to enzymatic inactivation by trypsin.
AB - The cyclic melanotropin Ac-Ser1-Tyr2-Ser3-Cys4-Glu6-His6-Phe7-Arg8-Trp9-Cys10-Lys11-Pro12-Val13-NH2is a highly potent agonist as determined in several melanocyte bioassays. In linear melanotropins, a D-Phe7substitution leads to increased potency and often prolonged biological activity. In order to determine if this substitution would have the same effect in cyclic melanotropins, we have prepared a series of these analogues. The D-Phe7-substituted cyclic melanotropins Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_10-NH2 and Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_n-NH2were both more potent than their cyclic L-Phe7-containing counterparts in either the frog or lizard skin bioassay by more than a factor of 10. Neither peptide, however, exhibited prolongation of biological activity in either assay. Substitution of D-Phe7into the cyclic 4–12 and 4~13 sequences led to a slight or no increase in potency in both assays relative to the L-Phe7counterparts, but the activity of the melanotropins was ultraprolonged in each assay. Ac- [Cys4,D-Phe7,Cys10]-α-MSH4_12-NH2was about equipotent to Ac-[Cys4,D-Phe7,Cys10]-α-MSH4_13-NH2, again demonstrating as with certain linear and cyclic L-Phe7-containing melanotropins, that the C-terminal amino acid valine is not required for biological activity or for superpotency. Similar to the linear D-Phe7analogues that possessed ultraprolonged melanotropic activity, the 4–12 and 4–13 cyclic D-Phe7analogues also displayed the phenomenon of superagonism, which is a time-dependent increase in efficacy over that produced by an equipotent concentration of the native hormone. Cyclization of certain linear melanotropins resulted in analogues with increased resistance to biological degradation by serum enzymes or purified proteolytic enzymes. Further, incorporation of a D-Phe7into in the cyclic analogues led to melanotropins that were totally resistant to enzymatic inactivation by trypsin.
UR - http://www.scopus.com/inward/record.url?scp=0021998835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021998835&partnerID=8YFLogxK
U2 - 10.1021/jm50001a008
DO - 10.1021/jm50001a008
M3 - Article
C2 - 2985783
AN - SCOPUS:0021998835
SN - 0022-2623
VL - 28
SP - 583
EP - 588
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 5
ER -